Nisa Investment Advisors LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Nisa Investment Advisors LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 345,569 shares of the biopharmaceutical company's stock after selling 63,224 shares during the quarter. Nisa Investment Advisors LLC's holdings in Gilead Sciences were worth $38,721,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $1,789,254,000. FMR LLC boosted its position in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the period. GAMMA Investing LLC boosted its position in Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock worth $285,761,000 after buying an additional 2,532,070 shares during the period. Northern Trust Corp boosted its position in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the period. Finally, Royal Bank of Canada lifted its holdings in shares of Gilead Sciences by 30.1% during the fourth quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock worth $801,655,000 after purchasing an additional 2,005,863 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Gilead Sciences stock traded up $1.30 during midday trading on Thursday, reaching $114.54. The company had a trading volume of 6,096,837 shares, compared to its average volume of 7,706,475. The company has a market capitalization of $142.48 billion, a P/E ratio of 24.11, a P/E/G ratio of 0.73 and a beta of 0.29. The firm's fifty day simple moving average is $107.62 and its 200-day simple moving average is $104.50. Gilead Sciences, Inc. has a 12-month low of $68.14 and a 12-month high of $119.96. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period last year, the company posted ($1.32) EPS. The business's revenue was down .3% on a year-over-year basis. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.76%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on GILD. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Oppenheimer reduced their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $111.38.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the transaction, the chief financial officer directly owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. This trade represents a 1.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $110.45, for a total value of $1,104,500.00. Following the sale, the chief executive officer owned 615,725 shares of the company's stock, valued at $68,006,826.25. This trade represents a 1.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 58,500 shares of company stock valued at $6,340,745 in the last ninety days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.